Crown Bioscience is a global contract research organisation (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology. We partner with biotech and pharmaceutical companies to deliver integrated preclinical and translational research solutions, supporting programmes from target discovery through to clinical development.  

Our portfolio includes more than 2,800 patient-derived xenograft (PDX) models and approximately 1,000 tumour organoid models across 35 cancer indications, supported by expertise in in vivo, in vitro, ex vivo and in silico research. 

Combined with advanced laboratory services, multiomics capabilities and data science, we help generate the insights needed to support confident decision-making throughout the drug development continuum. 

Operating from 9 facilities across the US, Europe, and APAC, our laboratories meet the highest industry standards and include CAP-, CLIA- and ISO 15189-accredited facilities. 

To learn more, visit www.crownbio.com.